Yashmin Afshar

Dr. Yashmin Afshar


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MYMohammad Javad Yousefi
Mohammad Javad Yousefi
YAYashmin Afshar
Yashmin Afshar
AAAmirmohammad Amoozadehsamakoosh
Amirmohammad Amoozadehsamakoosh
ANAlma Naseri
Alma Naseri
FSFereshteh Soltani
Fereshteh Soltani
NRNima Rezaei
Nima Rezaei
Innate-like T cells (ILTCs) have recently emerged as a new target of several cancer immunotherapies. Some unique features, such as rapid MHC-independent recognition of antigens, performing heterogeneous anti-tumor activities, and being less susceptible to tumor-induced suppression, suggest promising roles of ILTCs in cancer immunology. On the other hand, these cells exhibit a dualistic nature in cancer, which includes both pro-tumor and anti-tumor effects, highlighting the importance of the complex regulatory environment of their functioning and activation. The functions and evolution of ILTC are greatly influenced by microRNAs (miRNAs), small non-coding RNA molecules that mediate post-transcriptional regulation. Considering the kind of ILTCs, miRNA, and cancer type, this interaction resembles both a tumor promoter and suppressor. ILTC functions and evolution are closely associated with microRNAs (miRNAs), small noncoding RNA molecules that play posttranscriptional regulatory roles. Depending on the type of ILTCs, miRNA, and cancer, this interaction resembles both a Tumor promoter and a tumor Suppressor. This review addresses the complicated relationship between ILTCs and different miRNAs, such as miR-155, let-7 s, and miR-181a, expressed in tumor cells, ILTCs, or packed in tumor-derived exosomes. We will underscore the synergetic effects of the expression of miRNA in tumor and immune cells, influencing ILTC’s function and cancer progression. We emphasized the recent and innovative therapeutic approaches, novel delivery systems, and CAR-T cell-based strategy, and the therapeutic potential of modifying the expression of miRNA to regulate the miRNA expression to modulate ILTC activity and improve cancer treatment.

8 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YAYashmin Afshar
Yashmin Afshar
AGAli Goli
Ali Goli
MAMelika Abrishami
Melika Abrishami
Resistant mechanisms to venetoclax, a selective BCL-2 inhibitor approved for hematological malignancies, are frequently mediated by the G101V mutation in BCL-2. Sonrotoclax illustrates superior potency against both wild-type and G101V-mutated BCL-2, yet the mechanistic basis remains unclear. This study employed computational methods to investigate the binding dynamics of both inhibitors. Structures were predicted with AlphaFold, refined via molecular dynamics simulations (MDS), and ligands were docked with AutoDock Vina. Four systems were subjected to triplicate 200 ns MDS, with analyses including RMSD, RMSF, buried surface area, protein-ligand interaction fingerprint, and MM/GBSA binding free energies. Results indicate venetoclax exhibits progressive dissociation from G101V BCL-2, with elevated RMSD, reduced buried surface area, and increased unbound states. In contrast, Sonrotoclax maintains a steady correlation, shows persistence with entropy-enthalpy compensation, displays negligible unbound time, higher binding free energies, and constant van der Waals anchors. Having all these results in mind, a "Dynamic Blockade" hypothesis is proposed, where Sonrotoclax's flexibility enables sustained BH3 groove occupancy, blocking pro-apoptotic BH3-only proteins and overcoming allosteric perturbations induced by G101V. This mechanistic perspective proposes the optimal approach for designing resilient inhibitors to accelerate drug repurposing and development in oncology.